Journal article
Canadian Clinical Experience on Switching From Standard Half‐life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half‐life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada
Abstract
This is a plain language summary on switching from the medicine octocog alfa to a new medicine damoctocog alfa pegol (BAY 94-9027, Jivi) for the treatment of haemophilia A in Canada.
Authors
Matino D; Chan AKC; Decker K; Iserman E; Edginton AN; Oladoyinbo O; Trinari E; Keepanasseril A; Iorio A
Journal
Haemophilia, , ,
Publication Date
October 14, 2025
DOI
10.1111/hae.70145
ISSN
1351-8216